With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck ...

Under the terms of the deal, MSD (known as Merck & Co in the US and Canada) is paying $30 million upfront for Modifi with up ...

Members of Harvard’s governing boards and faculty donated more than $2.3 million to political candidates and causes ahead of ...

Modifi Biosciences, Inc., a leader in the development of direct DNA modification enabled cancer therapeutics, has been ...

After the disastrous performance of 2022, the market has recovered better than expected and is on a growth trajectory.

All adults aged 50 and older should receive a vaccine against bacteria that can cause pneumonia and meningitis, federal ...

Shortly after Bicara Therapeutics raised more than $360 million in an IPO, the cancer biotech and its former parent company ...

Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...

Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

In a report released today, Carter Gould from Barclays maintained a Buy rating on Merck & Company (MRK – Research Report), with a ...

Merck’s acquisition of Modifi Biosciences will give it access to preclinical cancer drug candidates that target DNA repair ...

The acquisition strengthens Merck's oncology portfolio as the company looks to off the expiration of the patent for ...